Pharming

Three blocks displaying from left to right a person a handshake and another person
Biotech

Pharming pays $66M for Abliva, mitochondrial disease med

Pharming is paying $66.1 million to acquire the Swedish biotech Abliva and its phase 2-stage med for a type of mitochondrial disease.
James Waldron Dec 16, 2024 4:39am
traffic light green light

Pharming shares pivotal data on ex-Novartis rare disease drug

Apr 1, 2022 8:20am
Novartis headquarters

Novartis sells phase 3 rare disease drug to Pharming

Aug 13, 2019 7:35am